The SIMPLE trial found the 5-day remdesivir treatment arm to be 65% more likely to have clinical improvement compared with standard of care alone in patients with moderate COVID-19.
Emerging Infectious Diseases
Here's this week's roundup of the latest coronavirus-related news.
Officials with the FDA have approved Octapharma’s investigational new drug (IND) application for intravenous immune globulin (IVIG) (Human, Octagam 10%) therapy.
Here's a roundup of the latest coronavirus-related news.
Hydroxychloroquine has been widely used for treatment of COVID-19, despite the lack of strong evidence supporting its efficacy.
Today, the American Society of Health-System Pharmacists (ASHP) sent a letter to Vice President Mike Pence to urge the transparent and orderly allocation of remdesivir among hospitals
Roche received FDA Emergency Use Authorization for its anti-SARS-CoV-2 antibody test, Elecsys.
Officials with the FDA have issued an emergency use authorization for remdesivir (Gilead Sciences) for the treatment of suspected or laboratory-confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults and children.
New clinical trial updates on remdesivir as a potential treatment for coronavirus disease 2019 (COVID-19) were announced today.
Famotidine, the active compound in an OTC heartburn drug, may disable a key enzyme that COVID-19 uses to replicate.